Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global expansion with Cartistem, its allogeneic human umbilical cord blood-derived ...